Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Public ClinicalTrials.gov record NCT03797326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.
Study identification
- NCT ID
- NCT03797326
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 611 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2019 (Actual)
- Primary completion
- Oct 28, 2024 (Actual)
- Completion
- Oct 28, 2024 (Actual)
- Last update posted
- May 4, 2026
2019 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope ( Site 0002) | Duarte | California | 91010 | — |
| Cedars Sinai Medical Center ( Site 0003) | Los Angeles | California | 90048 | — |
| University of California Davis Comprehensive Cancer Center ( Site 0005) | Sacramento | California | 95817 | — |
| University of Colorado, Anschutz Cancer Pavilion ( Site 0007) | Aurora | Colorado | 80045 | — |
| University of Florida-Health Cancer Center-Orlando ( Site 0015) | Orlando | Florida | 32806 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0009) | New Brunswick | New Jersey | 08901 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023) | New York | New York | 10016 | — |
| Sanford Fargo Medical Center ( Site 0059) | Fargo | North Dakota | 58102 | — |
| Lehigh Valley Hospital- Cedar Crest ( Site 0047) | Allentown | Pennsylvania | 18103 | — |
| Sanford Cancer Center ( Site 0058) | Sioux Falls | South Dakota | 57104 | — |
| West Cancer Center - East Campus ( Site 0018) | Germantown | Tennessee | 38138 | — |
| Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049) | Dallas | Texas | 75230 | — |
| Swedish Medical Center ( Site 0021) | Seattle | Washington | 98104 | — |
| University of Wisconsin Carbone Cancer Center ( Site 0017) | Madison | Wisconsin | 53792-0001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03797326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03797326 live on ClinicalTrials.gov.